CellRapeutics™ In Vivo CAR-M Cell Engineering Service

Are you constrained by prolonged timelines, exorbitant production costs, and the persistent challenge of achieving sustained efficacy in solid tumors using conventional cell therapies? Creative Biolabs offers an integrated In vivo CAR-MA Development platform designed to overcome these barriers. By utilizing a non-viral mRNA-LNP delivery system engineered for myeloid-specific targeting, we enable direct in vivo generation of CAR-equipped macrophages, which bypasses complex ex vivo manufacturing, enhances deep tumor infiltration, and actively reprograms the immunosuppressive TME, accelerating the path to durable, off-the-shelf immunotherapies.

Introduction

CAR-MA exert multi-faceted anti-tumor effects by mediating targeted phagocytosis through chimeric antigen receptors, remodeling the tumor microenvironment, and synergizing with adaptive immunity. The in vivo application of CAR-MA not only holds the potential to overcome immunosuppressive barriers in solid tumors but also represents a promising strategic direction for achieving durable and safe cellular therapies.

Fig.1 Immunomodulatory Functions of CAR-MA.¹

CellRapeutics™ In Vivo CAR-M Cell Engineering Service at Creative Biolabs

Creative Biolabs' CellRapeutics™ In Vivo CAR-M Cell Engineering Service delivers end-to-end solutions for creating targeted macrophage therapies. We engineer myeloid-specific CAR constructs, optimize proprietary LNP formulations for in vivo mRNA delivery, and validate systemic efficacy in advanced humanized tumor models, bypassing costly ex vivo manufacturing while enabling solid tumor penetration, TME reprogramming, and durable anti-tumor responses.

What We Can Offer

Our platform offers an integrated suite of advanced technologies for in vivo CAR-macrophage development, encompassing targeted lipid nanoparticle delivery, engineered viral vectors, synergistic co-delivery systems, and intelligent dual-signaling CAR architectures to achieve precise cell reprogramming and potent anti-tumor efficacy.

Our platform extends the reach of in vivo immune cell engineering beyond T cells, offering two targeted services designed to harness the unique therapeutic potential of B cells and NK cells.

• In vivo B Cell Engineering Service

We reprogram B cells in vivo to secrete therapeutic antibodies or cytokines, enabling long-term protein replacement and immunomodulation with minimal manufacturing complexity.

• In vivo CAR-NK Cell Engineering Service

We engineer NK cells in vivo with chimeric antigen receptors, delivering potent, targeted antitumor immunity with reduced risk of cytokine release syndrome and graft-versus-host disease.

Our Service Process

Required starting materials:

• Target Antigen Data: Detailed information on the specific Tumor-Associated Antigen (TAA) of interest, including expression profile, specificity, and affinity data.
• CAR Sequence/Format Requirements: Preliminary design specifications for the CAR construct (e.g., scFv sequence, co-stimulatory domains, signaling domains) or a clear anti-TAA antibody sequence.
• Disease Model Specifications: Target indication (e.g., Hepatocellular Carcinoma (HCC), solid tumors) and any existing pre-clinical model data or cell lines you wish to utilize.

Key Steps:

Final Deliverables:

• Mechanistic Data Package: Confirmation of CAR expression, M1 polarization status, TME activation, and cytokine profiles
• Lead LNP-mRNA Formulation: Complete manufacturing protocol and analytical data for the optimized LNP-mRNA product.

Key Advantages

• Solid Tumor Penetration: Leveraging the natural migratory capabilities of macrophages, our CAR-MAs are inherently effective at infiltrating deep into the solid tumor microenvironment, a key limitation for many traditional CAR-T therapies.
• TME Reprogramming: The CAR-MA mechanism extends beyond direct killing (phagocytosis). It actively remodels the immunosuppressive TME toward a pro-inflammatory state and promotes epitope spreading, which recruits and activates the patient's endogenous T cells for a multi-faceted and durable anti-tumor response.

FAQ

Why Choose Us?

As experts in cellular immunotherapy and metabolism, we are committed to delivering cutting-edge solutions. By selecting our In vivo CAR-MA Development Service, you gain access to CAR-macrophages engineered via a non-viral mRNA/LNP delivery platform. Our advanced approach overcomes the penetration barriers of solid tumors and actively reprograms the immunosuppressive TME.

Customer Reviews

"The implementation of Creative Biolabs' In vivo CAR-MA platform in our study has markedly enhanced the targeting precision of CAR delivery to myeloid-lineage cells. This approach enables the reliable in situ generation of CAR-macrophages, effectively eliminating concerns regarding off-target transduction."— Dr. La Hn.

"Employing Creative Biolabs' In vivo CAR-MA Development system has accelerated the advancement of therapeutic candidates targeting bulky, treatment-resistant solid tumors. This strategy exhibits robust antitumor activity and efficient T-cell recruitment, outcomes that were not achievable with previous ex vivo-engineered T-cell methodologies."— Dr. An Fx.

"Utilization of the In vivo CAR-MA platform from Creative Biolabs has substantially expedited the iterative optimization of CAR architectures and subsequent dosing regimens. This has shortened our preclinical development schedule by several months while allowing more precise management of the therapeutic index."— Dr. Pl Sh.

How to Contact Us?

Ready to advance your next therapeutic breakthrough? Contact our expert scientific team for comprehensive technical consultations, tailored partnership models, and to initiate a collaborative project scoping discussion.

Reference

1. Huang T, Bei C, Hu Z, Li Y. CAR-macrophage: Breaking new ground in cellular immunotherapy. Front Cell Dev Biol. 2024 Oct 3; 12:1464218. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fcell.2024.1464218.